NCT02679261View on ClinicalTrials.gov

Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Bicuspid Aortic Valve
Interventions
DRUG

Atorvastatin

Oral administration atorvastatin 20 mg per day

DRUG

Placebo

Oral administration placebo

Trial Locations (10)

28007

Hospital General Universitario Gregorio Marañón, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

30120

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

36200

Hospital Universitario de Vigo, Vigo

41071

Hospital Universitario Virgen de la Macarena, Seville

43204

Hospital Universitari Sant Joan de Reus, Reus

47005

Hospital Clínico Universitario de Valladolid, Valladolid

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08035

Hospital Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT02679261 - Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve | Biotech Hunter | Biotech Hunter